Replicate human clinical trials preclinically with our diverse PDX panels. MCTs provide robust, statistically powered data for efficacy, biomarker validation, and patient stratification to de-risk clinical phases.

Combine the scalability of 3D in vitro organoids (PDO/PDXO) with matched in vivo PDX models for a seamless translational workflow. Ideal for high-throughput screening and confident model selection.

Test drug candidates using patient tumor tissue that maintains the native tumor microenvironment and intact endogenous immune cells. Highly predictive for I/O and oncology drug responses.

Utilize our advanced 3D in vitro BMN models, which accurately replicate the complex bone marrow microenvironment. This platform enables robust screening for hematological malignancies (e.g., AML, MM).